Evolus (NASDAQ:EOLS) Downgraded by Zacks Investment Research

Zacks Investment Research downgraded shares of Evolus (NASDAQ:EOLS) from a hold rating to a sell rating in a research note released on Thursday, Zacks.com reports.

According to Zacks, “Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. “

Other equities analysts have also recently issued reports about the stock. Mizuho set a $31.00 price objective on shares of Evolus and gave the stock a buy rating in a research report on Monday, May 20th. Stifel Nicolaus set a $33.00 price objective on shares of Evolus and gave the stock a buy rating in a research report on Wednesday, July 31st. JMP Securities lowered their price objective on shares of Evolus from $35.00 to $30.00 and set a market outperform rating on the stock in a research report on Tuesday, August 13th. They noted that the move was a valuation call. Cantor Fitzgerald reiterated a buy rating and set a $35.00 price objective on shares of Evolus in a research report on Tuesday, April 30th. Finally, ValuEngine upgraded shares of Evolus from a hold rating to a buy rating in a research report on Thursday, July 18th. Two analysts have rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $26.78.

NASDAQ EOLS opened at $14.05 on Thursday. Evolus has a twelve month low of $10.22 and a twelve month high of $30.25. The company has a current ratio of 5.01, a quick ratio of 14.52 and a debt-to-equity ratio of 1.87. The firm’s 50 day moving average price is $16.51 and its two-hundred day moving average price is $20.48.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings data on Monday, August 12th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($0.96) by ($0.41). The business had revenue of $2.30 million for the quarter, compared to analysts’ expectations of $0.29 million. Sell-side analysts forecast that Evolus will post -3.43 earnings per share for the current year.

In related news, Director David N. Gill purchased 2,000 shares of the stock in a transaction dated Thursday, June 13th. The shares were acquired at an average cost of $13.65 per share, for a total transaction of $27,300.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Corp Alphaeon sold 5,307,940 shares of the business’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $19.25, for a total transaction of $102,177,845.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have bought 1,302,791 shares of company stock worth $25,058,164. 3.90% of the stock is currently owned by corporate insiders.

Several institutional investors have recently bought and sold shares of EOLS. Edge Wealth Management LLC purchased a new position in shares of Evolus during the 2nd quarter valued at $29,000. Patriot Financial Group Insurance Agency LLC boosted its holdings in Evolus by 50.0% in the first quarter. Patriot Financial Group Insurance Agency LLC now owns 1,500 shares of the company’s stock worth $34,000 after purchasing an additional 500 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its holdings in Evolus by 2,224.0% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,324 shares of the company’s stock worth $34,000 after purchasing an additional 2,224 shares in the last quarter. Meeder Asset Management Inc. boosted its holdings in Evolus by 48.9% in the first quarter. Meeder Asset Management Inc. now owns 1,732 shares of the company’s stock worth $39,000 after purchasing an additional 569 shares in the last quarter. Finally, Pearl River Capital LLC boosted its holdings in Evolus by 217.7% in the first quarter. Pearl River Capital LLC now owns 1,906 shares of the company’s stock worth $44,000 after purchasing an additional 1,306 shares in the last quarter. Institutional investors and hedge funds own 15.54% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Read More: Why is the ex-dividend date different from the record date?

Get a free copy of the Zacks research report on Evolus (EOLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.